About the book
The approach to radiopharmaceuticals development has expanded over the years. The first approach, most probably when Henri Alexandre Danlos and Eugene Bloch placed radium in contact with a tuberculosis skin lesion in 1901, was conducted in order to develop the use of radioactivity for medical use. In 1936, John H. Lawrence made the first clinical therapeutic application of an artificial radionuclide when he used phosphorus-32 to treat leukemia. These different activities with the passage of time were continuously translated into advanced theranostic techniques commonly known as Nuclear Medicine Techniques (NMT), which are mainly based on radiopharmaceuticals. More recently, radiopharmaceuticals are developed based on advanced knowledge in molecular biology techniques, which aim to better understand and define the target specificity, accuracy and binding sites for radiopharmaceuticals. As a result of these advances in NMT, deep seated and functional disorders related issues have been resolved. This book intends to provide the reader with a comprehensive overview on the radionuclide physics, development of radiopharmaceuticals, the role of radiopharmaceuticals in medical imaging and therapy of deep seated and functional disorders, advances in NMT with emphasis on target-based radiopharmaceuticals development, and prospects in the field of medical imaging.